Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology
Nutriband (NASDAQ:NTRB) filed a provisional patent application with the USPTO on October 8, 2025 to strengthen intellectual property covering its AVERSA™ transdermal abuse deterrent technology. The filing targets improved aversive formulations and coating application methods designed to enhance deterrence for patches containing opioids and stimulants.
The company notes AVERSA is already covered by issued patents in 46 countries and says conversion to a non‑provisional application and a subsequent patent grant could extend U.S. patent protection (statutory term starts from the non‑provisional filing date).
Nutriband (NASDAQ:NTRB) ha depositato una domanda di brevetto provvisoria presso l'USPTO l'8 ottobre 2025 per rafforzare la proprietà intellettuale che copre la sua tecnologia AVERSA™ deterrente transdermico contro l'abuso. La domanda mira a formulazioni avversive migliorate e a metodi di applicazione del rivestimento progettati per aumentare il deterrente per i cerotti contenenti oppiacei e stimolanti.
L'azienda segnala che AVERSA è già coperta da brevetti assegnati in 46 paesi e afferma che la conversione in una domanda non provvisoria e una successiva concessione di brevetto potrebbero estendere la protezione brevettuale negli Stati Uniti (il termine legale parte dalla data di deposito della domanda non provvisoria).
Nutriband (NASDAQ:NTRB) presentó una solicitud de patente provisional ante la USPTO el 8 de octubre de 2025 para fortalecer la propiedad intelectual que cubre su tecnología AVERSA™ deterrente transdérmico contra el abuso. La presentación busca mejorar formulaciones aversivas y métodos de aplicación del recubrimiento diseñados para aumentar la disuasión en parches que contienen opioides y estimulantes.
La empresa señala que AVERSA ya está cubierta por patentes emitidas en 46 países y afirma que convertirla en una solicitud no provisional y obtener posteriormente una concesión de patente podría extender la protección de patentes en EE. UU. (el plazo legal comienza desde la fecha de presentación de la solicitud no provisional).
Nutriband (NASDAQ:NTRB)은 2025년 10월 8일 USPTO에 임시 특허 출원을 제출하여 AVERSA™ 경피성 남용 방지 기술에 대한 지적 재산권을 강화했습니다. 이 출원은 오피오이드 및 자극제를 함유한 패치에 대한 억제 효과를 높이기 위한 개선된 혐오성(formulations aversive) 제형과 코팅 적용 방법을 목표로 합니다.
회사는 AVERSA가 이미 46개국에서 발행 특허로 보호되고 있다고 밝히며, 비임시 출원으로의 전환과 이후 특허 허가가 미국 특허 보호를 연장할 수 있다고 말합니다(법적 기간은 비임시 출원의 접수일로부터 시작됩니다).
Nutriband (NASDAQ:NTRB) a déposé une demande de brevet provisoire auprès de l'USPTO le 8 octobre 2025 afin de renforcer la propriété intellectuelle couvrant sa technologie AVERSA™ dispositif de dissuasion contre l’abus transdermique. Le dépôt vise à améliorer les formulations aversives et les méthodes d’application du revêtement destinées à accroître le caractère dissuasif des patchs contenant des opioïdes et des stimulant.
L’entreprise note qu’AVERSA est déjà protégée par des brevets délivrés dans 46 pays et indique que la conversion en une demande non provisoire et l’obtention ultérieure d’un brevet pourraient prolonger la protection par brevet aux États-Unis (la durée légale commence à partir de la date de dépôt de la demande non provisoire).
Nutriband (NASDAQ:NTRB) hat am 8. Oktober 2025 beim USPTO einen vorläufigen Patentantrag eingereicht, um das geistige Eigentum an der AVERSA™ transdermalen Missbrauchsbegang-Technologie zu stärken. Die Einreichung zielt auf verbesserte aversive Formulierungen und Beschichtungsanwendungsmethoden ab, die die Abschreckung bei Pflastern mit Opioiden und Stimulanzien erhöhen sollen.
Das Unternehmen weist darauf hin, dass AVERSA bereits durch erteilte Patente in 46 Ländern geschützt ist, und erklärt, dass eine Umwandlung in einen nicht-provisorischen Antrag und eine anschließende Patentvergabe den US-Patentschutz verlängern könnte (die gesetzliche Laufzeit beginnt ab dem Datum der nicht-provisorischen Anmeldung).
Nutriband (NASDAQ:NTRB) قدمت طلب براءة اختراع مؤقتة لدى USPTO في 8 أكتوبر 2025 لتعزيز الملكية الفكرية التي تغطي تقنيتها AVERSA™ مثبطة إساءة الاستخدام عبر الجلد. يهدف التقديم إلى تحسين التركيبات المقاومة للاستخدام السيئ وطرق تطبيق الطلاء المصممة لتعزيز الردع لللاصقات التي تحتوي على مواد أفيونية ومنشطات.
تشير الشركة إلى أن AVERSA محمي بالفعل ببراءات صادرة في 46 دولة وتقول إن التحويل إلى طلب غير مؤقت وإعطاء براءة لاحقة قد يطيلان الحماية الأمريكية (يبدأ الأجل القانوني من تاريخ تقديم الطلب غير المؤقت).
Nutriband (NASDAQ:NTRB) 已于 2025 年 10 月 8 日向 USPTO 提交了一个临时专利申请，以加强覆盖其 AVERSA™ 经皮抗滥用技术 的知识产权。该申请旨在改进厌恶性配方和涂层应用方法，旨在提升对含阿片类药物和兴奋剂的贴片的威慑效果。
公司表示 AVERSA 已在 46 个国家获得已发专利保护，并表示将其转为非临时申请并取得后续的专利授权，可能会延长美国的专利保护（法定期限自非临时申请日期起算）。
- Filed a provisional USPTO application on Oct 8, 2025 to strengthen AVERSA IP
- Provisional covers improved aversive formulations and coating application methods
- AVERSA already has patents issued in 46 countries
- Provisional status requires conversion to a non‑provisional filing and grant to extend U.S. patent term
- Any U.S. patent term extension depends on the non‑provisional filing date rather than the provisional date
Insights
Nutriband filed a provisional patent on
The filing targets improved aversive formulations and coating methods for the AVERSA™ transdermal technology, which is intended to deter oral abuse and reduce accidental exposure for patches containing opioids and stimulants. Strengthening formulation and application‑method claims can broaden enforceable coverage and, if converted to a non‑provisional application and granted, may extend exclusivity tied to the
Key dependencies and risks include successful conversion to a non‑provisional application, patent prosecution outcomes, and the specific claim scope that issues; none of these are guaranteed by the provisional filing. Watch for conversion to a non‑provisional filing and subsequent USPTO prosecution actions over the next 12–36 months as concrete milestones that determine whether this filing materially strengthens enforceable protection.
Nutriband files provisional patent application to enhance its AVERSA™ transdermal abuse deterrent technology being developed for patches containing opioids and stimulants with a potential for abuse.
Nutriband’s AVERSA™ abuse-deterrent technology consists of a proprietary aversive agent coating that employs taste aversion to deter oral abuse and reduce accidental exposure.
ORLANDO, Fla., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) to further strengthen Nutriband’s intellectual property protection for its AVERSA™ abuse deterrent transdermal technology.
The provisional patent application covers improved aversive formulations and coating application methods to enhance the abuse deterrent properties of Nutriband’s AVERSA™ transdermal technology and make it even more difficult to defeat. If this provisional patent application is converted into a non-provisional patent application and a new patent is subsequently granted, it could significantly extend the patent protection for products that utilize Nutriband’s AVERSA™ abuse deterrent technology as the statutory patent term of a US patent is 20 years from the non-provisional filing date.
The AVERSA™ abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
Nutriband’s AVERSA™ abuse-deterrent technology can be utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as opioids, while making sure that these drugs remain accessible to those patients who really need them.
About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, including opioids and stimulant drugs, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
SOURCE: Nutriband Inc.
FAQ
What did Nutriband (NTRB) announce on October 8, 2025?
How does the October 2025 provisional filing affect Nutriband's AVERSA patent protection?
What technology is covered by Nutriband's provisional patent application (NTRB)?
Does Nutriband already have international patents for AVERSA?
Will the provisional patent immediately extend NTRB's patent term?
